You are on page 1of 2

Treatment comparison between tiamulin and tylosin against mixed enteric infection with PRRS co-infection in Thailand

P. Poolperm 1, N. Rattanawanichroj 1, S. Punthum 1, W. Navasakuljinda 1, C. Ananratanakul 1, S. Talummuk 1, M. Makhanon 2, U. Klein 3

Swine Medicine Group, Kasetsart University Kamphangsaen, Thailand. 2Novartis Ltd Animal Health BU, Bangkok, Thailand. 3 Novartis Animal Health Inc., Basel, Switzerland.

Surveillance data on the prevalence of mixed bacterial enteric infections indicate the importance of those infections 1,2. Lawsonia intracellularis and Brachyspira spp. are commonly identified as causative pathogens within batches of affected pigs. The growth performances are affected and pigs take longer to recover. Multiple infectious agents influence the choice of treatment. Feed medication is the most important method to control enteric diseases in fattening pigs 3,4. Tiamulin and tylosin are common antimicrobials used for this purpose in Thailand. The objective of this field study was to compare the effect of feed medication with tiamulin and tylosin on the health status and performance of pigs in a Thai pig farm where mixed enteric infections and PRRS co-infection were present.

Brachyspira spp. and absence of Salmonella were confirmed in pre-screening disease monitoring tests (IFA test, culture). The farm was PRRS positive. Laboratory tests of faeces (continuously) and blood (week 12, 14, 18, 22) samples were conducted during the trial. Lawsonia intracellularis and Brachyspira spp. were identified. The ELISA tests confirmed the PRRS co-infection on the farm. 960 commercial crossbred pigs at nine weeks of age were divided into two groups. Each group had equal number of male and female in sex-separated pens at 20 pigs per pen and 16 pens per house, AIAO system. Groups of 480 pigs were treated (group 1: Tylosin premix 150 ppm or 5 mg/kg bw; group 2: Tiamulin premix 150 ppm or 5mg/kg bw) for five weeks in starter and two weeks in grower feed. After the second treatment block in the grower, there was no feed medication in both groups until the end of finishing. Pigs with clinical signs at that time period were treated individually by injection.

Pigs were weighed individually four times: at the beginning of trial, at the end of starter, grower and finisher stages before sending pigs to slaughterhouses. The pigs were scored weekly for diarrhoea and respiratory infections. Feed consumption, cost of feed and medication were recorded for each group. In the economic projection different economical and performance parameters were calculated in order to show the effect of the feed medication on the production parameters. The growth performance parameters e.g. ADG, FCR, FCG (feed cost per kilogram weight gain) were recorded and compared between the two groups by GLM in SAS 7.0.

The results of the trial are summarized
in Table 1. Significant differences (p<0.05) in the ADG, FCR and FCG were found between the treatment groups during the starter period. At the end of the trial in pigs medicated with tiamulin premix improved of ADG (+2.3%), FCR

Material and Methods

The trial was conducted in a farrowfinish farm. Presence of Lawsonia,

Table 1. Performance and economic results

Result No. of pigs start/end Av.weight (kg) start Av.weight (kg) end starter period Av.weight (kg) end of trial ADG (g/day) starter period ADG (g/day) total FCR starter period FCR total FCG at starter (EURO) FCG at the end of trial (EURO) Margin/pig (EURO) Return on investment (ROI)
a,bMeans in a row with different superscripts differ (p<0.05) Margin/pig =Value live weight-cost of feed and medication ROI(%)=100*Margin/Cost of feed and medication

tylosin 480/461 27.60 51.93


tiamulin 480/464 27.47 54.01b 94.10


Diff. vs. tylosin 0/+3 -0.13 +2.08 +1.11 +11.5% +2.3% -8.5% -3.8% -8.5% -3.8% +1.33 +3%

92.99 675.62 2.11


753.34 b 722.40 1.93 b 2.52

705.97 2.62 0.566


0.518 b 0.554 51.737 145.7%

0.576 50.411 142.7%

(-3.8%) and FCG (-3.8%) when compared to pigs in the other treatment group. No differences were found in the mortality/ culling rate between both groups.

end of the fattening period. As a result, the improved production performance in the tiamulin group resulted in an additional margin/pig (+1.33) and a higher return on investment (+3%).

3. McOrist, S. (2005). Proceedings of the 2nd Asian Pig Veterinary Society Congress, 15-27. 4. Taylor, D.J. and Trott, D.J. (1997). Intestinal Spirochetes in Domestic Animal and Humans, 211-241.

The results demonstrate the positive effect of strategic medication during the production phases on the farm. The beneficial effect of tiamulin in the treatment of the mixed enteric and PRRS co-infection leads to improved performance results, particularly during the starter period and finally at the

1. Thomson J. (2001). Animal Health Research Reviews 2 (1), 31-36. 2. Thomson J. (2005). Proceedings Ileitis Colitis Workshop Brazil 81-85.

Denagard is a registered trademark of Novartis AG, Basel, Switzerland. 2011 Novartis Animal Health Inc.